ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2125

Pleiotropy of a Positive Antinuclear Antibody (ANA) Test: A Phewas and GWAS Approach

Vivian Kawai1, Jonathan Mosley2, QiPing Feng1, Wei-Qi Wei3, Daniel Carranza Leon2, Cecilia P. Chung4, Andrea Ihegword2 and C Michael Stein1, 1Vanderbilt University Medical Center, Nashville, TN, 2Medicine, Vanderbilt University Medical Center, Nashville, TN, 3Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, 4Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ANA, GWAS, Lupus and phenotypes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: ANAs are almost always present in systemic lupus erythematosus (SLE), but they are also present in ~12-20% of the population. A positive ANA (ANA+) can precede the onset of SLE, but for the vast majority the clinical consequences are unknown.  In animal models, naturally occurring ANAs can protect against renal disease. The genetics of SLE are well established but those of ANA+ are poorly defined. We hypothesized that ANA+ is associated with increased risk of SLE-like phenotypes and that ANA+ and SLE share the same genetic structure.

Methods: Using BioVU, a DNA biobank linked to de-identified electronic medical records, we performed a phenome wide association study (PheWAS) and a genome wide association study (GWAS) in patients who had ANA tested as part of clinical care and had genotypes available. Phecodes were assigned using standard hierarchical grouping of ICD9 codes, and logistic regression performed adjusting for age, race and sex. Patients with an SLE phecode (645.4*) were excluded from the PheWAS.  For the GWAS analysis, genotyping was performed using the MEGA Illumina Chip with standard quality control procedures and SNPs with a MAF ≥ 1% included. Genetic associations with ANA+ were analyzed using an additive model with logistic regression adjusted for age, sex, and top three principal components.

Results: PheWAS analysis included 10097 patients of whom 4406 were ANA+. ANA+ was associated with increased risk for several autoimmune disorders (e.g., rheumatoid arthritis, systemic sclerosis) but with reduced risk for renal and hypertensive disorders (Fig. 1).  The GWAS analysis included ~8.6 million SNPs and 5085 patients, 2139 of whom were ANA+.  None of the associations were GWAS significant, but 118 SNPs had a P<1×10-5. None of these SNPs were previously associated with SLE but mapped to loci (VAV3, NCOA1, LOC285696, ADAMTS19, RPS12, CYP2R1, KKR1 and CACNG2) associated with immune thyroiditis, nephropathies, cancer, vitamin D levels, metabolic and psychiatric phenotypes (Fig. 2).

Conclusion: We found that ANA+ in patients without SLE had the expected association with other autoimmune disorders; however, there was an unexpected association with reduced risk of renal and hypertension phenotypes. There was no strong overlap in the genetic structure of SLE and ANA+.



Disclosure: V. Kawai, None; J. Mosley, None; Q. Feng, None; W. Q. Wei, None; D. Carranza Leon, None; C. P. Chung, None; A. Ihegword, None; C. M. Stein, None.

To cite this abstract in AMA style:

Kawai V, Mosley J, Feng Q, Wei WQ, Carranza Leon D, Chung CP, Ihegword A, Stein CM. Pleiotropy of a Positive Antinuclear Antibody (ANA) Test: A Phewas and GWAS Approach [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/pleiotropy-of-a-positive-antinuclear-antibody-ana-test-a-phewas-and-gwas-approach/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pleiotropy-of-a-positive-antinuclear-antibody-ana-test-a-phewas-and-gwas-approach/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology